Browse Multiple Sclerosis Articles by Topic

Tolebrutinib May Slow Disability Progression in Patients with SPMS

A recent prospective study showed that tolebrutinib slows disability progression in patients with nonrelapsing secondary progressive multiple sclerosis (SPMS). There were some safety concerns, especially hepatotoxicity. A lack of demonstrated effect on some functional outcomes warrants careful consideration and continuing study.

The Effect of High-Dose Vitamin D on Clinically Isolated Syndrome and MS

This study by Thouvenot et al evaluated the effectiveness of high-dose vitamin D treatment on clinically isolated syndrome and early multiple sclerosis as monotherapy and reported a reduced incidence of new disease activity compared to the control group.

Long-Term Efficacy of Ocrelizumab as First-Line Treatment for Relapsing-Remitting Multiple Sclerosis

Nine-year follow-up data from open-label extension of the Phase III clinical trials of ocrelizumab show that, although the efficacy of ocrelizumab was maintained throughout the duration of the study, patients who were treated with ocrelizumab from the beginning of the Phase III trials did better than the patients who were on subcutaneous (SC) interferon β-1a initially and were switched to ocrelizumab at the onset of the open-label extension period.

Acute Clinical Worsening Without MRI Changes in Multiple Sclerosis

Patients with multiple sclerosis (MS) can have an acute clinical event suggestive of a relapse, but their magnetic resonance imaging (MRI) shows no corresponding changes (labeled by the authors as an acute clinical event with stable MRI [ACES]). These events have not been systematically analyzed. The authors reported that this number is significant, and a quarter of the relapses reported by patients fall under this category. Patients with ACES had higher relapse rates and a greater risk of transition to secondary progressive MS.

Multiple Sclerosis Disease Burden May Be Underestimated

Prescription drug prices, indirect productivity loss drive care costs significantly higher for these patients compared to others.

Multiple Sclerosis and Immune Response to COVID-19 Vaccination

A large group of patients with multiple sclerosis taking various disease-modifying therapies did not respond uniformly to COVID-19 vaccination.

Infections Before Age 20 Years Increase the Risk of Multiple Sclerosis

Researchers found patients diagnosed with infection in adolescence were at higher risk for multiple sclerosis, even after exclusion of infectious mononucleosis, pneumonia, and central nervous system infection.

Multiple Sclerosis and Vascular Disease

Researchers evaluated the presence and pathological significance of extracranial systemic and cerebral small vessel disease in patients with multiple sclerosis (MS) compared to healthy controls. MS patients exhibited less systemic vascular disease and more small vessel disease in the brain vs. controls.

Even Moderate COVID-19 Cases Can Cause Serious Neurological Problems

Strokes, seizures, and movement disorders just a few complications observed.

Ibudilast Shows Promise for the Treatment of Progressive MS

A Phase II trial of ibudilast in progressive multiple sclerosis demonstrated a decreased rate of brain atrophy when compared to placebo.